A novel potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), IC50=1.7 μM. Pre or post ischemia treatment (40 mg/kg) with GPI-16552 reduces brain infarct volumes in a rat model of cerebral ischemia. It modulates the inflammatory response to ischemia/reperfusion in a rat splanchnic artery...
Know who made it. See the evidence. Buy through one marketplace.
A novel potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), IC50=1.7 μM. Pre or post ischemia treatment (40 mg/kg) with GPI-16552 reduces brain infarct volumes in a rat model of cerebral ischemia. It modulates the inflammatory response to ischemia/reperfusion in a rat splanchnic artery occlusion model and reduces the degree of spinal cord inflammation and tissue injury after experimental spinal cord trauma. Synergizes with temozolomide in decreasing melanoma cell invasion and metastatic spreading in mice injected with B16 melanoma cells
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
